转移性肾癌基于免疫检查点抑制剂治疗的单中心经验总结  

Summary of single-center experience in the treatment of metastatic renal cancer based on immune checkpoint inhibitors

作　　者：蒋炳良 黄超[1] 刘正升[1] 赵仲杰 王涛[1] 罗雨 吴准[1] 张开颜[1] 李伟[1] 陈斌[1] 邢金春[1] 王雪刚[1] JIANG Bingliang;HUANG Chao;LIU Zhengsheng;ZHAO Zhongjie;WANG Tao;LUO Yu;WU Zhun;ZHANG Kaiyan;LI Wei;CHEN Bin;XING Jinchun;WANG Xuegang(Department of Urology,First Affiliated Hospital of Xiamen University,Xiamen,Fujian,361003,China)

机构地区：[1]厦门大学附属第一医院泌尿外科,福建厦门361003

出　　处：《临床泌尿外科杂志》2024年第11期989-994,共6页Journal of Clinical Urology

摘　　要：目的:总结基于免疫检测点抑制剂在转移性肾癌(metastatic renal cell carcinoma,mRCC)治疗中的单中心治疗经验。方法:回顾性分析2019年7月—2020年7月厦门大学附属第一医院收治61例应用程序性死亡蛋白-1(programmed cell death protein-1,PD-1)单抗治疗的晚期mRCC患者的临床资料。根据一线治疗方法将患者分为2组。一线单用靶向治疗24例(A组),男18例,女6例;透明细胞癌20例,非透明细胞癌4例;行原发灶切除术10例。一线靶向联合免疫治疗37例(B组),男29例,女8例;透明细胞癌30例,非透明细胞癌7例;行原发灶切除18例。2组患者一般资料比较均差异无统计学意义(P>0.05)。靶向治疗药物包括阿昔替尼、舒尼替尼、培唑帕尼、依维莫司、索拉非尼、仑伐替尼,免疫治疗药物包括替雷利珠单抗。一线单用靶向治疗患者在疾病进展后更换为免疫联合靶向治疗或其他靶向药物治疗方案,一线靶向联合免疫治疗患者在疾病进展或不能耐受后根据患者情况更换其他靶免方案或单纯靶向药物继续治疗;分析mRCC患者总体人群和各亚组的客观缓解率(objective response rate,ORR)、无进展生存期(progression-free survival,PFS)、总生存时间(overall survival,OS)等。结果:61例中位随访时间24(12,43)个月,A、B组的中位OS分别为39(26,未达)个月、49(22,67)个月,中位PFS分别为6(3,11)个月、13(9,18)个月;A、B组的2年OS率分别为66%、76%,5年OS率分别为38%、49%。在靶免联合基础上既往接受过原发灶切除手术患者预后优于原发灶未切除患者(P=0.008),前者中位OS未达到,后者中位OS为24(19,29)个月。单因素分析结果显示,OS与原发灶切除、使用阿昔替尼相关(P<0.01),相较于未切除原发灶的患者,原发灶切除患者死亡风险下降约70%(HR=0.39,95%CI:0.17~0.89,P=0.026),而治疗过程中应用阿昔替尼的患者死亡风险下降约75%(HR=0.25,95%CI:0.06~0.98,P=0.047)。8例一线治疗单用靶向治疗�Objective To summarize the experience of diagnosis and treatment of metastatic renal cell carcinoma(mRCC) patients treated with targeted drugs at a single center.Methods The clinical data of 61 mRCC patients treated with programmed cell death protein-1(PD-1) monoclonal antibody at First Affiliated Hospital of Xiamen University from July 2019 to July 2020 were retrospectively analyzed. According to the first-line treatment method, the patients were divided into two groups. Group A(24 cases) received single-agent targeted therapy as the first-line treatment, including 18 males and 6 females, 20 clear cell carcinoma cases and 4 non-clear cell carcinoma cases;10 cases underwent nephrectomy. Group B(37 cases) received targeted combined immunotherapy as the first-line treatment, including 29 males and 8 females, 30 clear cell carcinoma cases and 7 non-clear cell carcinoma cases, 18 cases underwent nephrectomy. There were no statistically significant differences in the general data of the two groups(P>0.05). The targeted therapy drugs included axitinib, sunitinib, pazopanib, everolimus, sorafenib and lenvatinib. The immunotherapy drug included tislelizumab. Patients who received single-agent targeted therapy in the first line were switched to immune-combined targeted therapy or other targeted drug regimens after disease progression, while patients who received first-line targeted therapy combined with immunotherapy were switched to other targeted therapy regimens or continued with pure targeted drug therapy after disease progression or intolerance. The overall population and subgroups of patients with mRCC were analyzed for objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) etc.Results Among the 61 patients, the median follow-up time was 24(12, 43) months. The median OS was 39(26, not reached) months for group A and 49(22, 67) months for group B, and the median PFS was 6(3, 11) months for group A and 13(9, 18) months for group B. The 2-year survival rate were 66% for group A and 76

关 键 词：转移性肾癌 靶向治疗 免疫治疗 

分 类 号：R737.11[医药卫生—肿瘤]